Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.41 |
| ▸ | MTTP | P55157 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4450295 | 1.00 | TNFRSF1A (0.41) | TNFRSF1AMTTPLMNAALDH1A1KCNH2 | |
| SCHEMBL4454648 | 0.90 | TACR1 (0.43) | TNFRSF1AMTTPALDH1A1KCNH2KMT2A | |
| SCHEMBL4454644 | 0.90 | TACR1 (0.43) | TNFRSF1AMTTPALDH1A1KCNH2KMT2A | |
| SCHEMBL4446586 | 0.82 | TNFRSF1A (0.46) | TNFRSF1ALMNAALDH1A1KCNH2HTT | |
| SCHEMBL4446583 | 0.82 | TNFRSF1A (0.46) | TNFRSF1ALMNAALDH1A1KCNH2HTT | |
| SCHEMBL4443078 | 0.81 | TNFRSF1A (0.46) | TNFRSF1ALMNAALDH1A1HTTKMT2A | |
| SCHEMBL3638466 | 0.81 | TNFRSF1A (0.46) | TNFRSF1ALMNAALDH1A1HTTKMT2A | |
| SCHEMBL4450981 | 0.80 | TNFRSF1A (0.45) | TNFRSF1ALMNAALDH1A1KCNH2HTT | |
| SCHEMBL4450978 | 0.80 | TNFRSF1A (0.45) | TNFRSF1ALMNAALDH1A1KCNH2HTT | |
| SCHEMBL4456780 | 0.79 | MEN1 (0.47) | TNFRSF1ALMNAALDH1A1KCNH2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
| WO-2008141446-A1 | AMINO ACID DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | TNFRSF1A 3963/4885MTTP 2378/4885LMNA 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.